

# Ann H Partridge

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4656424/publications.pdf>

Version: 2024-02-01

225  
papers

17,713  
citations

16411

64  
h-index

15218

126  
g-index

227  
all docs

227  
docs citations

227  
times ranked

15571  
citing authors

#	ARTICLE	IF	CITATIONS
1	American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients. <i>Journal of Clinical Oncology</i> , 2006, 24, 2917-2931.	0.8	1,800
2	Fertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 1994-2001.	0.8	979
3	Web-Based Survey of Fertility Issues in Young Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 4174-4183.	0.8	675
4	Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 134-141.	13.9	598
5	Nonadherence to Adjuvant Tamoxifen Therapy in Women With Primary Breast Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 602-606.	0.8	593
6	Screening, Assessment, and Care of Anxiety and Depressive Symptoms in Adults With Cancer: An American Society of Clinical Oncology Guideline Adaptation. <i>Journal of Clinical Oncology</i> , 2014, 32, 1605-1619.	0.8	558
7	Cancer and fertility preservation: international recommendations from an expert meeting. <i>BMC Medicine</i> , 2016, 14, 1.	2.3	521
8	Patient adherence and persistence with oral anticancer treatment. <i>Ca-A Cancer Journal for Clinicians</i> , 2009, 59, 56-66.	157.7	496
9	Adherence to Therapy With Oral Antineoplastic Agents. <i>Journal of the National Cancer Institute</i> , 2002, 94, 652-661.	3.0	477
10	Goserelin for Ovarian Protection during Breast-Cancer Adjuvant Chemotherapy. <i>New England Journal of Medicine</i> , 2015, 372, 923-932.	13.9	452
11	Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 556-562.	0.8	432
12	Prospective Study of Fertility Concerns and Preservation Strategies in Young Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1151-1156.	0.8	313
13	Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. <i>Journal of Clinical Oncology</i> , 2016, 34, 3308-3314.	0.8	297
14	Biology of breast cancer in young women. <i>Breast Cancer Research</i> , 2014, 16, 427.	2.2	296
15	Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient-Level Data. <i>Journal of Clinical Oncology</i> , 2018, 36, 1981-1990.	0.8	268
16	Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors. <i>Journal of Clinical Oncology</i> , 2015, 33, 2254-2261.	0.8	232
17	Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1868-1875.	0.8	229
18	Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3307-3329.	0.8	210

#	ARTICLE	IF	CITATIONS
19	ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). <i>Breast</i> , 2017, 35, 203-217.	0.9	203
20	The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). <i>BMJ Open</i> , 2019, 9, e026797.	0.8	182
21	Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. <i>Fertility and Sterility</i> , 2010, 94, 638-644.	0.5	173
22	A Standard Set of Value-Based Patient-Centered Outcomes for Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 677.	3.4	167
23	Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 543-553.	0.8	162
24	Risk Perceptions and Psychosocial Outcomes of Women With Ductal Carcinoma In Situ: Longitudinal Results From a Cohort Study. <i>Journal of the National Cancer Institute</i> , 2008, 100, 243-251.	3.0	153
25	Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus recommendations from The North American Menopause Society and The International Society for the Study of Women's Sexual Health. <i>Menopause</i> , 2018, 25, 596-608.	0.8	143
26	Second international consensus guidelines for breast cancer in young women (BCY2). <i>Breast</i> , 2016, 26, 87-99.	0.9	142
27	Informing Clinical Trial Participants About Study Results. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 363.	3.8	140
28	First international consensus guidelines for breast cancer in young women (BCY1). <i>Breast</i> , 2014, 23, 209-220.	0.9	135
29	The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. <i>Cancer</i> , 2010, 116, 791-798.	2.0	131
30	Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused Update. <i>Journal of Clinical Oncology</i> , 2018, 36, 2433-2443.	0.8	131
31	Age of menopause among women who remain premenopausal following treatment for early breast cancer: Long-term results from International Breast Cancer Study Group Trials V and VI. <i>European Journal of Cancer</i> , 2007, 43, 1646-1653.	1.3	130
32	Risk-Based Health Care, the Cancer Survivor, the Oncologist, and the Primary Care Physician. <i>Seminars in Oncology</i> , 2013, 40, 804-812.	0.8	125
33	Body image in recently diagnosed young women with early breast cancer. <i>Psycho-Oncology</i> , 2013, 22, 1849-1855.	1.0	123
34	Adherence and Persistence With Oral Adjuvant Chemotherapy in Older Women With Early-Stage Breast Cancer in CALGB 49907: Adherence Companion Study 60104. <i>Journal of Clinical Oncology</i> , 2010, 28, 2418-2422.	0.8	116
35	Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. <i>Lancet Oncology</i> , The, 2021, 22, e303-e313.	5.1	116
36	Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2016, 34, 2416-2427.	0.8	112

#	ARTICLE	IF	CITATIONS
37	Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2556-2564.	3.2	109
38	<i>BRCA1</i> and <i>BRCA2</i> Mutation Testing in Young Women With Breast Cancer. <i>JAMA Oncology</i> , 2016, 2, 730.	3.4	105
39	Anxiety and Depression in Young Women With Metastatic Breast Cancer: A Cross-Sectional Study. <i>Psychosomatics</i> , 2018, 59, 251-258.	2.5	105
40	Effect of Age on Breast Cancer Outcomes in Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From a Herceptin Adjuvant Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 2692-2698.	0.8	99
41	The Effect of Age on Delay in Diagnosis and Stage of Breast Cancer. <i>Oncologist</i> , 2012, 17, 775-782.	1.9	97
42	Pregnancy after breast cancer: Are young patients willing to participate in clinical studies?. <i>Breast</i> , 2015, 24, 201-207.	0.9	97
43	Treatment-related amenorrhea and sexual functioning in young breast cancer survivors. <i>Cancer</i> , 2014, 120, 2264-2271.	2.0	93
44	Offering participants results of a clinical trial: sharing results of a negative study. <i>Lancet</i> , The, 2005, 365, 963-964.	6.3	92
45	Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial. <i>Oncologist</i> , 2020, 25, 310-318.	1.9	92
46	Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 525-534.	1.1	91
47	Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin. <i>Journal of Clinical Oncology</i> , 2018, 36, 682-688.	0.8	90
48	Supportive care after curative treatment for breast cancer (survivorship care): Resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. <i>Breast</i> , 2013, 22, 606-615.	0.9	87
49	Randomized trial of a physical activity intervention in women with metastatic breast cancer. <i>Cancer</i> , 2016, 122, 1169-1177.	2.0	87
50	Effect of the LIVESTRONG at the YMCA exercise program on physical activity, fitness, quality of life, and fatigue in cancer survivors. <i>Cancer</i> , 2017, 123, 1249-1258.	2.0	87
51	Pregnancy-Associated Cancer: A U.S. Population-Based Study. <i>Journal of Women's Health</i> , 2019, 28, 250-257.	1.5	87
52	Fertility and adjuvant treatment in young women with breast cancer. <i>Breast</i> , 2007, 16, 175-181.	0.9	84
53	Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, <i>ERBB2</i> -Negative Metastatic Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 1598.	3.4	84
54	Ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy in cancer patients: From biological evidence to clinical application. <i>Cancer Treatment Reviews</i> , 2019, 72, 65-77.	3.4	83

#	ARTICLE	IF	CITATIONS
55	Pregnancy after breast cancer: if you wish, maâ€™am. Breast Cancer Research and Treatment, 2011, 129, 309-317.	1.1	81
56	Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer. Annals of Surgical Oncology, 2015, 22, 3809-3815.	0.7	81
57	Developing a Service Model That Integrates Palliative Care Throughout Cancer Care: The Time Is Now. Journal of Clinical Oncology, 2014, 32, 3330-3336.	0.8	80
58	Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk. Journal of Clinical Oncology, 2020, 38, 2762-2772.	0.8	80
59	Management of breast cancer in very young women. Breast, 2015, 24, S154-S158.	0.9	79
60	Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials. Annals of Surgical Oncology, 2017, 24, 3534-3540.	0.7	76
61	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. Journal of Clinical Oncology, 2021, 39, 2375-2385.	0.8	76
62	The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. Breast, 2018, 42, 41-49.	0.9	75
63	Cancer Treatment-Related Infertility: A Critical Review of the Evidence. JNCI Cancer Spectrum, 2019, 3, pkz008.	1.4	75
64	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. Journal of Clinical Oncology, 2020, 38, 4184-4193.	0.8	74
65	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology, 2021, 39, 3293-3305.	0.8	70
66	Fertility and Menopausal Outcomes in Young Breast Cancer Survivors. Clinical Breast Cancer, 2008, 8, 65-69.	1.1	69
67	Pregnancy After Breast Cancer in Patients With Germline <i>BRCA</i> Mutations. Journal of Clinical Oncology, 2020, 38, 3012-3023.	0.8	69
68	Lasting effects of cancer and its treatment on employment and finances in adolescent and young adult cancer survivors. Cancer, 2019, 125, 1908-1917.	2.0	66
69	Partner support and anxiety in young women with breast cancer. Psycho-Oncology, 2015, 24, 1679-1685.	1.0	65
70	Chemotherapy-related amenorrhea after adjuvant paclitaxelâ€™trastuzumab (APT trial). Breast Cancer Research and Treatment, 2015, 151, 589-596.	1.1	65
71	CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. Journal of Clinical Oncology, 2022, 40, 1323-1334.	0.8	62
72	Oncology Physician and Nurse Practices and Attitudes Regarding Offering Clinical Trial Results To Study Participants. Journal of the National Cancer Institute, 2004, 96, 629-632.	3.0	61

#	ARTICLE	IF	CITATIONS
73	Effect of Sustained Smoking Cessation Counseling and Provision of Medication vs Shorter-term Counseling and Medication Advice on Smoking Abstinence in Patients Recently Diagnosed With Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1406.	3.8	61
74	Menopausal symptoms and fertility concerns in premenopausal breast cancer survivors. <i>Menopause</i> , 2011, 18, 105-108.	0.8	60
75	Young Women with Breast Cancer: A Focus Group Study of Unmet Needs. <i>Journal of Adolescent and Young Adult Oncology</i> , 2013, 2, 153-160.	0.7	59
76	Time to incorporate germline multigene panel testing into breast and ovarian cancer patient care. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 393-410.	1.1	58
77	Loss of RasGAP Tumor Suppressors Underlies the Aggressive Nature of Luminal B Breast Cancers. <i>Cancer Discovery</i> , 2017, 7, 202-217.	7.7	57
78	The definition of pregnancy-associated breast cancer is outdated and should no longer be used. <i>Lancet Oncology</i> , The, 2021, 22, 753-754.	5.1	57
79	Breast Cancer in Young Women. <i>JAMA Oncology</i> , 2015, 1, 877.	3.4	54
80	Self-reported adherence to oral cancer therapy: relationships with symptom distress, depression, and personal characteristics. <i>Patient Preference and Adherence</i> , 2015, 9, 1587.	0.8	52
81	Preoperative Psychosocial and Psychophysical Phenotypes as Predictors of Acute Pain Outcomes After Breast Surgery. <i>Journal of Pain</i> , 2019, 20, 540-556.	0.7	51
82	Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). <i>Breast Cancer Research and Treatment</i> , 2016, 159, 109-118.	1.1	47
83	Model Program to Improve Care for a Unique Cancer Population: Young Women With Breast Cancer. <i>Journal of Oncology Practice</i> , 2012, 8, e105-e110.	2.5	46
84	Contralateral prophylactic mastectomy in women with breast cancer: trends, predictors, and areas for future research. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 447-452.	1.1	46
85	Estimates of Young Breast Cancer Survivors at Risk for Infertility in the U.S.. <i>Oncologist</i> , 2014, 19, 814-822.	1.9	46
86	Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 725-733.	0.8	46
87	Association of post-diagnosis cardiorespiratory fitness with cause-specific mortality in cancer. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2020, 6, 315-322.	1.8	43
88	The Rodent Liver Undergoes Weaning-Induced Involution and Supports Breast Cancer Metastasis. <i>Cancer Discovery</i> , 2017, 7, 177-187.	7.7	42
89	Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2408-2419.	0.8	42
90	Study protocol for Young & Strong: a cluster randomized design to increase attention to unique issues faced by young women with newly diagnosed breast cancer. <i>BMC Public Health</i> , 2015, 15, 37.	1.2	41

#	ARTICLE	IF	CITATIONS
91	Symptoms and Symptom Attribution Among Women on Endocrine Therapy for Breast Cancer. <i>Oncologist</i> , 2015, 20, 598-604.	1.9	40
92	Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 243-251.	1.1	40
93	Psychosocial needs of young breast cancer survivors in Mexico City, Mexico. <i>PLoS ONE</i> , 2018, 13, e0197931.	1.1	39
94	The impact of young age at diagnosis (age <40 years) on prognosis varies by breast cancer subtype: A U.S. SEER database analysis. <i>Breast</i> , 2022, 61, 77-83.	0.9	38
95	Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer. <i>Cancer</i> , 2019, 125, 3266-3274.	2.0	37
96	Perceptions and Management Approaches of Physicians Who Care for Women with Ductal Carcinoma In Situ. <i>Clinical Breast Cancer</i> , 2008, 8, 275-280.	1.1	35
97	Desired Elements and Timing of Cancer Survivorship Care: One Approach May Not Fit All. <i>Journal of Oncology Practice</i> , 2014, 10, e293-e298.	2.5	35
98	Interventions to Enhance Adherence to Oral Antineoplastic Agents: A Scoping Review. <i>Journal of the National Cancer Institute</i> , 2020, 112, 443-465.	3.0	35
99	Trajectories of fear of cancer recurrence in young breast cancer survivors. <i>Cancer</i> , 2022, 128, 335-343.	2.0	33
100	ABCDE Steps to Prevent Heart Disease in Breast Cancer Survivors. <i>Circulation</i> , 2014, 130, e157-9.	1.6	32
101	Fertility Preservation in Patients With Breast Cancer: Necessity, Methods, and Safety. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 355-363.	2.3	32
102	Prediction of Persistent Pain Severity and Impact 12 Months After Breast Surgery Using Comprehensive Preoperative Assessment of Biopsychosocial Pain Modulators. <i>Annals of Surgical Oncology</i> , 2021, 28, 5015-5038.	0.7	31
103	Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy. <i>Breast</i> , 2021, 59, 327-338.	0.9	31
104	Local/regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). <i>Breast Cancer Research and Treatment</i> , 2019, 176, 303-310.	1.1	30
105	Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in young BRCA-mutated breast cancer patients. <i>Reproductive BioMedicine Online</i> , 2019, 38, 835-844.	1.1	29
106	Targeting Depressive Symptoms in Younger Breast Cancer Survivors: The Pathways to Wellness Randomized Controlled Trial of Mindfulness Meditation and Survivorship Education. <i>Journal of Clinical Oncology</i> , 2021, 39, 3473-3484.	0.8	29
107	Challenges in ductal carcinoma in situ risk communication and decision-making. <i>Ca-A Cancer Journal for Clinicians</i> , 2012, 62, 203-210.	157.7	27
108	Surveillance Mammography in Older Patients With Breast Cancer—Can We Ever Stop?. <i>JAMA Oncology</i> , 2017, 3, 402.	3.4	27



#	ARTICLE	IF	CITATIONS
109	Variability in diagnostic threshold for comedo necrosis among breast pathologists: implications for patient eligibility for active surveillance trials of ductal carcinoma in situ. <i>Modern Pathology</i> , 2019, 32, 1257-1262.	2.9	27
110	Perceptions, Attributions, and Emotions Toward Endocrine Therapy in Young Women with Breast Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2016, 5, 16-23.	0.7	26
111	Oncology Physicians' Perspectives on Practices and Barriers to Fertility Preservation and the Feasibility of a Prospective Study of Pregnancy After Breast Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2017, 6, 429-434.	0.7	26
112	Fatigue and physical activity in cancer survivors: A cross-sectional population-based study. <i>Cancer Medicine</i> , 2019, 8, 2535-2544.	1.3	26
113	Cancer Survivorship and the Young Breast Cancer Patient: Addressing the Important Issues. <i>Oncologist</i> , 2013, 18, e19-e20.	1.9	25
114	Emerging Data and Current Challenges for Young, Old, Obese, or Male Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2647-2654.	3.2	25
115	Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D. <i>Breast</i> , 2022, 65, 32-40.	0.9	25
116	The impact of sharing results of a randomized breast cancer clinical trial with study participants. <i>Breast Cancer Research and Treatment</i> , 2009, 115, 123-129.	1.1	23
117	Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors. <i>Cancer</i> , 2021, 127, 2888-2894.	2.0	23
118	Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care. <i>Journal of Clinical Oncology</i> , 2022, 40, 1111-1123.	0.8	23
119	Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 3190-3204.	0.8	23
120	Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 443-452.	3.0	22
121	Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and/or trastuzumab: a systematic review and meta-analysis. <i>Cancer Causes and Control</i> , 2021, 32, 1395-1405.	0.8	22
122	New Insights Into Nonadherence With Adjuvant Endocrine Therapy Among Young Women With Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv245.	3.0	21
123	Fertility concerns among breast cancer patients in Mexico. <i>Breast</i> , 2017, 33, 71-75.	0.9	21
124	Pregnancy after breast cancer: Results from a prospective cohort of young women with breast cancer. <i>Cancer</i> , 2021, 127, 1021-1028.	2.0	20
125	Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 249-258.	1.1	20
126	Informational needs and the quality of life of patients in their first year after metastatic breast cancer diagnosis. <i>Journal of Community and Supportive Oncology</i> , 2014, 12, 347-354.	0.1	20



#	ARTICLE	IF	CITATIONS
127	Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2339-2348.	3.2	20
128	Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. <i>Oncologist</i> , 2015, 20, 713-718.	1.9	19
129	Exogenous reproductive hormone use in breast cancer survivors and previvors. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 249-261.	12.5	19
130	The Patient's Voice: Adherence, Symptoms, and Distress Related to Adjuvant Endocrine Therapy After Breast Cancer. <i>International Journal of Behavioral Medicine</i> , 2020, 27, 687-697.	0.8	19
131	Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). <i>Breast Cancer Research and Treatment</i> , 2021, 189, 103-110.	1.1	19
132	Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. <i>Nature Communications</i> , 2021, 12, 5563.	5.8	19
133	Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go?. <i>Clinical Cancer Research</i> , 2017, 23, 2611-2616.	3.2	18
134	Association of Local Therapy With Quality-of-Life Outcomes in Young Women With Breast Cancer. <i>JAMA Surgery</i> , 2021, 156, e213758.	2.2	18
135	Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. <i>British Journal of Cancer</i> , 2022, 126, 302-309.	2.9	18
136	Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 2148-2162.	0.8	18
137	A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 63.	2.3	18
138	Evaluating the Utility of Baseline Cardiac Function Screening in Early-Stage Breast Cancer Treatment. <i>Oncologist</i> , 2016, 21, 666-670.	1.9	17
139	Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS). <i>JNCI Cancer Spectrum</i> , 2018, 2, pky063.	1.4	17
140	The Unique Reproductive Concerns of Young Women with Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2012, 732, 77-87.	0.8	17
141	Extended Therapy With Letrozole and Ovarian Suppression in Premenopausal Patients With Breast Cancer After Tamoxifen. <i>Clinical Breast Cancer</i> , 2014, 14, 413-416.	1.1	16
142	Survival benefit needed to undergo chemotherapy: Patient and physician preferences. <i>Cancer</i> , 2017, 123, 2821-2828.	2.0	16
143	Randomized trial of a clinic-based weight loss intervention in cancer survivors. <i>Journal of Cancer Survivorship</i> , 2018, 12, 186-195.	1.5	15
144	Identifying distinct trajectories of change in young breast cancer survivors' sexual functioning. <i>Psycho-Oncology</i> , 2019, 28, 1033-1040.	1.0	15

#	ARTICLE	IF	CITATIONS
145	Posttraumatic stress in breast cancer survivors diagnosed at a young age. <i>Psycho-Oncology</i> , 2020, 29, 1312-1320.	1.0	15
146	Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study. <i>Breast</i> , 2020, 52, 23-32.	0.9	15
147	Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 53-62.	1.1	15
148	Higher Stage of Disease Is Associated With Bilateral Mastectomy Among Patients With Breast Cancer: A Population-Based Survey. <i>Clinical Breast Cancer</i> , 2016, 16, 105-112.	1.1	13
149	Looking back, moving forward: the evolution of cancer survivorship care. <i>Lancet Oncology</i> , The, 2017, 18, 18-19.	5.1	13
150	Partners of young breast cancer survivors: a cross-sectional evaluation of psychosocial concerns, coping, and mental health. <i>Journal of Psychosocial Oncology</i> , 2020, 38, 670-686.	0.6	13
151	Estimation of historical control rate for a single arm de-escalation study " Application to the POSITIVE trial. <i>Breast</i> , 2020, 53, 1-7.	0.9	13
152	Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. <i>Npj Breast Cancer</i> , 2021, 7, 16.	2.3	13
153	The impact of fertility preservation on the timing of breast cancer treatment, recurrence, and survival. <i>Cancer</i> , 2021, 127, 3872-3880.	2.0	13
154	Randomized phase 2 trial of a coordinated breast cancer follow-up care program. <i>Cancer</i> , 2016, 122, 3546-3554.	2.0	12
155	A randomized study to improve care for young women with breast cancer at community and academic medical oncology practices in the United States: The Young and Strong study. <i>Cancer</i> , 2019, 125, 1799-1806.	2.0	12
156	Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 157-165.	1.1	12
157	Chemotherapy in Premenopausal Breast Cancer Patients. <i>Breast Care</i> , 2015, 10, 307-310.	0.8	11
158	Oncofertility: Fertile Ground for Conflict Between Patient Autonomy and Medical Values. <i>Oncologist</i> , 2017, 22, 860-863.	1.9	11
159	Assessment of Ovarian Function in Phase III (Neo)Adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation. <i>Journal of the National Cancer Institute</i> , 2021, , .	3.0	11
160	Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 99.	2.3	11
161	Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 117-124.	0.4	11
162	Implementing a breast cancer registry and treatment plan/summary program in clinical practice: A pilot program. <i>Cancer</i> , 2013, 119, 158-163.	2.0	10

#	ARTICLE	IF	CITATIONS
163	Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer. <i>Fertility and Sterility</i> , 2019, 112, 731-739.e1.	0.5	10
164	Contemporary management of breast cancer during pregnancy and subsequent lactation in a multicenter cohort of young women with breast cancer. <i>Breast Journal</i> , 2019, 25, 1104-1110.	0.4	10
165	Impact of Timing on Measurement of Decision Quality and Shared Decision Making: Longitudinal Cohort Study of Breast Cancer Patients. <i>Medical Decision Making</i> , 2019, 39, 642-650.	1.2	10
166	Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions. <i>JCO Oncology Practice</i> , 2022, 18, 211-216.	1.4	10
167	Body weight changes and associated predictors in a prospective cohort of young breast cancer survivors. <i>Cancer</i> , 2022, 128, 3158-3169.	2.0	10
168	Factors Affecting Surgical Decisions in Newly Diagnosed Young Women with Early-Stage Breast Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2019, 8, 463-468.	0.7	9
169	Body weight and return to work among survivors of early-stage breast cancer. <i>ESMO Open</i> , 2020, 5, e000908.	2.0	9
170	Young, Empowered and Strong: A Web-Based Education and Supportive Care Intervention for Young Women With Breast Cancer Across the Care Continuum. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 933-943.	1.0	9
171	Screening for Depression in Younger Breast Cancer Survivors: Outcomes From Use of the 9-item Patient Health Questionnaire. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab017.	1.4	8
172	Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab025.	1.4	8
173	Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1+ tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. <i>Future Oncology</i> , 2021, 17, 4665-4676.	1.1	8
174	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. <i>Npj Breast Cancer</i> , 2022, 8, 18.	2.3	8
175	Treatment of Breast Cancer in Young Adults. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 795-806.	1.8	8
176	Nonmalignant Diagnoses in Patients. <i>Journal of Clinical Oncology</i> , 2000, 18, 2636-2637.	0.8	7
177	Sexual Function among Women in Midlife: Findings from the Nurses' Health Study II. <i>Women's Health Issues</i> , 2019, 29, 291-298.	0.9	7
178	Challenges to Standardizing the Care for Adult Cancer Survivors: Highlighting ASCO's Fatigue and Anxiety and Depression Guidelines. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , 188-194.	1.8	6
179	Prospective evaluation of the impact of stress, anxiety, and depression on household income among young women with early breast cancer from the Young and Strong trial. <i>BMC Public Health</i> , 2020, 20, 1514.	1.2	6
180	Tumor phenotype and concordance in synchronous bilateral breast cancer in young women. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 815-821.	1.1	6

#	ARTICLE	IF	CITATIONS
181	Psychosocial issues and quality of life of parenting partners of young women with breast cancer. <i>Supportive Care in Cancer</i> , 2022, 30, 4265-4274.	1.0	6
182	A pilot videoconference group stress management program in cancer survivors: lessons learned. <i>Rural and Remote Health</i> , 2016, 16, 3863.	0.4	6
183	“œls it cancer or not?œA qualitative exploration of survivor concerns surrounding the diagnosis and treatment of ductal carcinoma in situ. <i>Cancer</i> , 2022, 128, 1676-1683.	2.0	6
184	Amenorrhea after lung cancer treatment. <i>Menopause</i> , 2019, 26, 306-310.	0.8	5
185	Aggressive Subsets of Metastatic Triple Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, e20-e26.	1.1	5
186	Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1105-1108.	3.0	5
187	Cancer Survivorship in Latin America: Current Status and Opportunities. <i>JCO Global Oncology</i> , 2021, 7, 1472-1479.	0.8	5
188	Nonmalignant Diagnoses in Patients. <i>Journal of Clinical Oncology</i> , 2000, 18, 2635-2636.	0.8	4
189	Evaluating the effect of esthetically enhanced materials compared to standard materials on clinician response rates to a mailed survey. <i>International Journal of Social Research Methodology: Theory and Practice</i> , 2013, 16, 301-306.	2.3	4
190	Chemo- and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2“Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. <i>Journal of Oncology Practice</i> , 2015, 11, 42-43.	2.5	4
191	Prevention of Premature Menopause and Preservation of Fertility in Young Cancer Survivors. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2625.	3.8	4
192	Evaluation of significant genome-wide association studies risk “ SNPs in young breast cancer patients. <i>PLoS ONE</i> , 2019, 14, e0216997.	1.1	4
193	Case“control study of heart rate abnormalities across the breast cancer survivorship continuum. <i>Cancer Medicine</i> , 2019, 8, 447-454.	1.3	4
194	Comparison of operative to monitoring and endocrine therapy for low-risk DCIS (COMET study).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS599-TPS599.	0.8	4
195	Comparison of Equations To Estimate Glomerular Filtration Rate and Their Impact on Frequency of Cisplatin-associated Acute Kidney Injury. <i>Kidney360</i> , 2021, 2, 205-214.	0.9	4
196	Pregnancy and breast cancer: epidemiology, treatment, and safety issues. <i>Oncology</i> , 2005, 19, 693-7; discussion 697-700.	0.4	4
197	Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	4
198	Risk communication and decision-making in the prevention of invasive breast cancer. <i>Breast</i> , 2017, 34, S55-S57.	0.9	3

#	ARTICLE	IF	CITATIONS
199	Feasibility and Acceptability of a Web Site to Promote Survivorship Care in Survivors of Hodgkin Disease. <i>JCO Clinical Cancer Informatics</i> , 2017, 1, 1-10.	1.0	3
200	Cyclophosphamide-Free Adjuvant Chemotherapy for the Potential Prevention of Premature Ovarian Insufficiency and Infertility in Young Women With Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1274-1276.	3.0	3
201	Symptom burden and employment status in breast cancer (BC) survivors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10073-10073.	0.8	3
202	Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1117-1126.	3.0	3
203	Does biomarker information impact breast cancer patients' preferences and physician recommendation for adjuvant chemotherapy?. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 545-553.	1.1	2
204	Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials. <i>Breast</i> , 2022, , .	0.9	2
205	Pregnancy after cancer: Timing is everything. <i>Cancer</i> , 2018, 124, 4290-4291.	2.0	1
206	Reproductive Health Issues for Young Women with Breast Cancer: Emerging Strategies for Difficult Situations. <i>Annals of Surgical Oncology</i> , 2019, 26, 1170-1172.	0.7	1
207	Clinical Benefit in the Treatment of Patients with Early Breast Cancer. <i>Breast</i> , 2019, 48, S115-S118.	0.9	1
208	The utility of magnetic resonance imaging in early-stage breast cancer survivors"An institutional experience and literature review. <i>Breast Journal</i> , 2020, 26, 1673-1679.	0.4	1
209	The effects of a clinic-based weight loss program on health-related quality of life and weight maintenance in cancer survivors: A randomized controlled trial. <i>Psycho-Oncology</i> , 2022, 31, 326-333.	1.0	1
210	Endocrine therapy non-persistence in young women with early-stage breast cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 531-531.	0.8	1
211	Is there a role for older-patient-specific cancer clinical trials? A pooled analysis of 2277 older patients in adjuvant breast cancer trials (Alliance A151715).. <i>Journal of Clinical Oncology</i> , 2018, 36, 10034-10034.	0.8	1
212	Mortality following breast cancer in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10511-10511.	0.8	1
213	Abstract P2-13-42: Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial. <i>Cancer Research</i> , 2022, 82, P2-13-42-P2-13-42.	0.4	1
214	Abstract P4-11-20: Attitudes and factors influencing contraception use over time in premenopausal women with early breast cancer in the prospective CANTO study. <i>Cancer Research</i> , 2022, 82, P4-11-20-P4-11-20.	0.4	1
215	The prevalence and predictors of adjuvant chemotherapy use among patients treated with neoadjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	1
216	Treatment of Breast Cancer During Pregnancy. <i>Current Breast Cancer Reports</i> , 2017, 9, 195-201.	0.5	0

#	ARTICLE	IF	CITATIONS
217	Reply to L. Del Mastro and A. Prat. Journal of Clinical Oncology, 2017, 35, 1139-1139.	0.8	0
218	Fertility Counseling and Preservation in Breast Cancer. Current Breast Cancer Reports, 2020, 12, 1-12.	0.5	0
219	A new look at old problems: Ovarian function suppression in the real world. Cancer, 2021, 127, 1174-1176.	2.0	0
220	Reply to M. Tanaka et al. Journal of Clinical Oncology, 2021, 39, JCO.21.01967.	0.8	0
221	Optimizing Decision Making for Ductal Carcinoma in Situ: Facts Over Fear. Journal of the National Cancer Institute, 2021, 113, 511-512.	3.0	0
222	Abstract PD5-06: Safety of assisted reproductive technologies (ART) following treatment completion in young women with germline <i>BRCA</i> pathogenic variants having a pregnancy after breast cancer. Cancer Research, 2022, 82, PD5-06-PD5-06.	0.4	0
223	Abstract PD5-05: Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial. Cancer Research, 2022, 82, PD5-05-PD5-05.	0.4	0
224	Overcoming Obstacles in Transitions of Cancer Survivor Care. Journal of the National Cancer Institute, 2022, , .	3.0	0
225	Auricular Acupuncture During Chemotherapy Infusion in Breast Cancer Patients: A Feasibility Study. , 2022, , .		0